Acuta Capital Partners LLC Sells 166,300 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Acuta Capital Partners LLC lowered its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 78.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 46,200 shares of the company's stock after selling 166,300 shares during the period. Dyne Therapeutics comprises 1.3% of Acuta Capital Partners LLC's holdings, making the stock its 23rd largest holding. Acuta Capital Partners LLC's holdings in Dyne Therapeutics were worth $1,660,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its holdings in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after acquiring an additional 669 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics in the 3rd quarter worth approximately $34,000. US Bancorp DE boosted its stake in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after purchasing an additional 1,212 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics during the third quarter worth $62,000. Finally, KBC Group NV raised its stake in Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company's stock worth $77,000 after buying an additional 751 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on DYN shares. Chardan Capital reaffirmed a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Oppenheimer restated an "outperform" rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $50.82.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox bought 32,000 shares of the business's stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares of the company's stock, valued at approximately $264,320. This represents a -133.33 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Susanna Gatti High sold 8,976 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. This trade represents a 6.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 176,257 shares of company stock worth $6,193,718. Corporate insiders own 20.77% of the company's stock.

Dyne Therapeutics Trading Up 6.5 %

Shares of DYN traded up $1.90 on Thursday, reaching $31.13. The company's stock had a trading volume of 1,411,494 shares, compared to its average volume of 1,480,310. Dyne Therapeutics, Inc. has a twelve month low of $10.12 and a twelve month high of $47.45. The stock has a market capitalization of $3.17 billion, a PE ratio of -8.74 and a beta of 1.10. The firm has a fifty day moving average of $31.89 and a 200-day moving average of $35.39.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.